ترجمه مقاله نقش ضروری ارتباطات 6G با چشم انداز صنعت 4.0
- مبلغ: ۸۶,۰۰۰ تومان
ترجمه مقاله پایداری توسعه شهری، تعدیل ساختار صنعتی و کارایی کاربری زمین
- مبلغ: ۹۱,۰۰۰ تومان
Neonatal brain injury including commonly hypoxic– ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), cerebral-intraventricular hemorrhage and hyperoxic brain damage is an important cause of neonatal mortality and subsequent sequelae such as cerebral palsy, mental retardation, learning disability, and epilepsy [1–3]. Although there are increasing evidence about underlying mechanisms and growing number of studies about treatment strategies, there is currently limited clinically utilized treatment for these common disorders. Epo is one of the most promising neuroprotective agents which was first identified as a humoral mediator that is involved in the maturation and proliferation of erythroid progenitor cells [4]. Over the last decade, neuroprotective actions of Epo and its underlying mechanisms in terms of signal transduction pathways have been defined and there is a growing interest in the potential therapeutic use of Epo for neuroprotection [5]. This article overviews the neuroprotective role of Epo on neonatal brain injury. Initially we discussed the existing data on the neuroprotective mechanisms of Epo and then discussed in detail the role of Epo as a neuroprotective agent against neonatal brain injury in animal models and clinical trials. Finally we have highlighted the safety concerns with the clinical use of Epo.